We claim:

1. A compound according to formula I



I

wherein

R_1 is H; C_1-C_4 alkyl; C_1-C_4 alkenyl; C_1-C_4 alkynyl or C_3-C_{10}cycloalkyl which are unsubstituted or substituted;

R_2 is H; C_1-C_4 alkyl; C_1-C_4 alkenyl; C_1-C_4 alkynyl or C_3-C_{10}cycloalkyl which are unsubstituted or substituted;

R_3 is H; -CF_3; -C_2F_5; C_1-C_4 alkyl; C_1-C_4 alkenyl; C_1-C_4 alkynyl; –CH_2-Z or R_2 and R_3 together with the nitrogen form a het ring;
Z is H; –OH; F; Cl; –CH_3; -CF_3; -CH_2Cl; -CH_2F or -CH_2OH;

R_4 is C_1-C_{16} straight or branched alkyl; C_1-C_{16} alkenyl; C_1-C_{16} alkynyl; or -C_3-C_{10}cycloalkyl; -$(CH_2)_{1-6}$-Z_1; -$(CH_2)_{0-6}$-aryl; and -$(CH_2)_{0-6}$-het; wherein alkyl, cycloalkyl and phenyl are unsubstituted or substituted;

Z_1 is –N(R_8)-C(O)-C_1-C_{10}alkyl; –N(R_8)-C(O)-$(CH_2)_{1-6}$-C_3-C_7cycloalkyl; –N(R_8)-C(O)-$(CH_2)_{0-6}$-phenyl; –N(R_8)-C(O)-$(CH_2)_{1-6}$-het; -C(O)-N(R_9)(R_{10}); -C(O)-O-C_1-C_{10}alkyl; -C(O)-O-$(CH_2)_{1-6}$-C_3-C_7cycloalkyl; -C(O)-O-$(CH_2)_{0-6}$-phenyl; -C(O)-O-$(CH_2)_{1-6}$-het; -O-C(O)-C_1-C_{10}alkyl; -O-C(O)-$(CH_2)_{1-6}$-C_3-C_7cycloalkyl; -O-C(O)-$(CH_2)_{0-6}$-phenyl; -O-C(O)-$(CH_2)_{1-6}$-het; wherein alkyl, cycloalkyl and phenyl are unsubstituted or substituted;

het is a 5-7 membered heterocyclic ring containing 1- 4 heteroatoms selected from N, O and S, or an 8-12 membered fused ring system including at least one 5-7 membered heterocyclic ring containing 1, 2 or 3 heteroatoms selected from N, O, and S, which heterocyclic ring or fused ring system is unsubstituted or substituted on a carbon or nitrogen atom;

R_8 is H; $-CH_3$; $-CF_3$; $-CH_2OH$ or $-CH_2Cl$;
R_9 and R_{10} are each independently H; C_1-C_4alkyl; C_3-C_7cycloalkyl; $-(CH_2)_{1-6}$-C_3-C_7cycloalkyl; $-(CH_2)_{0-6}$-phenyl; wherein alkyl, cycloalkyl and phenyl are unsubstituted or substituted, or R_9 and R_{10} together with the nitrogen form het;

R_5 is H; C_1-C_{10}-alkyl; aryl; phenyl; C_3-C_7cycloalkyl; $-(CH_2)_{1-6}$-C_3-C_7cycloalkyl; $-C_1$-C_{10}alkyl-aryl; $-(CH_2)_{0-6}$-C_3-C_7cycloalkyl-$(CH_2)_{0-6}$-phenyl; $-(CH_2)_{0-4}CH$-$((CH_2)_{1-4}$-phenyl$)_2$; $-(CH_2)_{0-6}$-CH(phenyl$)_2$; -indanyl; $-C(O)$-C_1-C_{10}alkyl; $-C(O)$-$(CH_2)_{1-6}$-C_3-C_7-cycloalkyl; $-C(O)$-$(CH_2)_{0-6}$-phenyl; $-(CH_2)_{0-6}$-$C(O)$-phenyl; $-(CH_2)_{0-6}$-het; $-C(O)$-$(CH_2)_{1-6}$-het; or R_5 is a residue of an amino acid, wherein the alkyl, cycloalkyl, phenyl and aryl substituents are unsubstituted or substituted;

U is as shown in structure II:



II

wherein
n = 0-5;
X is –CH or N;

Ra and Rb are independently an O, S, or N atom or C_{0-8} alkyl wherein one or more of the carbon atoms in the alkyl chain may be replaced by a heteroatom selected from O, S or N, and where the alkyl may be unsubstituted or substituted;
Rd is selected from:

(a) $-Re - Q - (Rf)_p(Rg)_q$; or

(b) $Ar_1–D– Ar_2$;

Rc is H or Rc and Rd may together form a cycloalkyl or het; where if Rd and Rc form a cycloalkyl or het, R_5 is attached to the formed ring at a C or N atom;
p and q are independently 0 or 1;
Re is C_{1-8} alkyl or alkylidene, and Re which may be unsubstituted or substituted;
Q is N, O, S, S(O), or $S(O)_2$;
Ar_1 and Ar_2 are substituted or unsubstituted aryl or het;

Rf and Rg are each independently H; -C_1-C_{10}alkyl; C_1-C_{10}alkylaryl; -OH; -O-C_1-C_{10}alkyl; -$(CH_2)_{0-6}$-C_3-C_7cycloalkyl; -O-$(CH_2)_{0-6}$-aryl; phenyl; aryl; phenyl-phenyl; -$(CH_2)_{1-6}$-het; -O-$(CH_2)_{1-6}$-het; -OR_{11}; -C(O)-R_{11}; –C(O)-N(R_{11})(R_{12}); -N(R_{11})(R_{12}); -S-R_{11}; -S(O)-R_{11}; -$S(O)_2$-R_{11}; -$S(O)_2$-$NR_{11}R_{12}$; -NR_{11}-$S(O)_2$- R_{12}; S-C_1-C_{10}alkyl; aryl-C_1-C_4alkyl; het-C_1-C_4-alkyl wherein alkyl, cycloalkyl, het and aryl are unsubstituted or substituted; -SO_2-C_1-C_2alkyl; -SO_2-C_1-C_2alkylphenyl; -O-C_1-C_4alkyl; or R_g and R_f form a ring selected from het or aryl;

D is –CO-; -C(O)-C_{1-7} alkylene or arylene; -CF_2-; -O-; -$S(O)_r$ where r is 0-2; 1,3dioaxolane; or C_{1-7} alkyl-OH; where alkyl, alkylene or arylene may be unsubstituted or substituted with one or more halogens, OH, -O-C_1-C_6alkyl, -S-C_1-C_6alkyl or -CF_3; or D is –N(Rh) wherein Rh is H; C_{1-7} alkyl (unsub or substituted); aryl; -O(C_{1-7}cycloalkyl) (unsub or substituted); C(O)-C_1-C_{10}alkyl; C(O)-C_o-C_{10}alkyl-aryl; C-O-C_1-C_{10}alkyl; C-O-C_o-C_{10}alkyl-aryl or SO_2-C_1-C_{10}-alkyl; SO_2-(C_o-C_{10}-alkylaryl);

R_6, R_7, R'_6 and R'_7 are each independently H; -C_1-C_{10} alkyl; -C_1-C_{10} alkoxy; aryl-C_1-C_{10} alkoxy; -OH; -O-C_1-C_{10}alkyl; -$(CH_2)_{0-6}$-C_3-C_7cycloalkyl; -O-$(CH_2)_{0-6}$-aryl; phenyl; -

$(CH_2)_{1-6}$-het; -O-$(CH_2)_{1-6}$-het; -OR_{11}; -C(O)-R_{11}; –C(O)-N(R_{11})(R_{12}); -N(R_{11})(R_{12}); -S-R_{11}; -S(O)-R_{11}; -$S(O)_2$-R_{11}; -$S(O)_2$-$NR_{11}R_{12}$; -NR_{11}-$S(O)_2$- R_{12}; wherein alkyl, cycloalkyl and aryl are unsubstituted or substituted; and R_6, R_7, R'_6 and R'_7 can be united to form a ring system;

R_{11} and R_{12} are independently H; C_1-C_{10} alkyl; -$(CH_2)_{0-6}$-C_3-C_7cycloalkyl; -$(CH_2)_{0-6}$-$(CH)_{0-1}$(aryl)$_{1-2}$; -C(O)-C_1-C_{10}alkyl; -C(O)-$(CH_2)_{1-6}$-C_3-C_7cycloalkyl; -C(O)-O-$(CH_2)_{0-6}$-aryl; -C(O)-$(CH_2)_{0-6}$-O-fluorenyl; -C(O)-NH-$(CH_2)_{0-6}$-aryl; -C(O)-$(CH_2)_{0-6}$-aryl; -C(O)-$(CH_2)_{1-6}$-het; -C(S)-C_1-C_{10}alkyl; -C(S)-$(CH_2)_{1-6}$-C_3-C_7cycloalkyl; -C(S)-O-$(CH_2)_{0-6}$-aryl; -C(S)-$(CH_2)_{0-6}$-O-fluorenyl; -C(S)-NH-$(CH_2)_{0-6}$-aryl; -C(S)-$(CH_2)_{0-6}$-aryl; -C(S)-$(CH_2)_{1-6}$-het; wherein alkyl, cycloalkyl and aryl are unsubstituted or substituted; or R_{11} and R_{12} are a substituent that facilitates transport of the molecule across a cell membrane; or R_{11} and R_{12} together with the nitrogen atom form het;
wherein the alkyl substituents of R_{11} and R_{12} may be unsubstituted or substituted by one or more substituents selected from C_1-C_{10}alkyl, halogen, OH, -O-C_1-C_6alkyl, -S-C_1-C_6alkyl or -CF_3;
substituted cycloalkyl substituents of R_{11} and R_{12} are substituted by one or more substituents selected from a C_1-C_{10} alkene; C_1-C_6alkyl; halogen; OH; -O-C_1-C_6alkyl; -S-C_1-C_6alkyl or -CF_3; and
substituted phenyl or aryl of R_{11} and R_{12} are substituted by one or more substituents selected from halogen; hydroxy; C_1-C_4 alkyl; C_1-C_4 alkoxy; nitro; -CN; -O-C(O)-C_1-C_4alkyl and –C(O)-O-C_1-C_4-aryl,
or pharmaceutically acceptable salts thereof.

2. A compound formula (I) according to claim 1 wherein
R_1 is H; -C_1-C_4 alkyl; -C_1-C_4 alkenyl; -C_1-C_4 alkynyl or cycloalkyl which are unsubstituted or substituted by one or more substituents selected from halogen, -OH, -SH, -OCH_3, -SCH_3, -CN, -SCN and nitro;

R_2 is H; -C_1-C_4alkyl; -C_1-C_4 alkenyl; -C_1-C_4 alkynyl or cycloalkyl which are unsubstituted or substituted by one or more substituents selected from halogen, -OH, -SH, -OCH_3, -SCH_3, -CN, -SCN and nitro;

R_3 is H; -CF_3; -C_2F_5; -C_1-C_4alkyl; -C_1-C_4alkenyl; -C_1-C_4alkynyl; –CH_2-Z or R_2 and R_3 together with the nitrogen form a het;
Z is H; –OH; F; Cl; –CH_3; -CF_3; -CH_2Cl; -CH_2F or –CH_2OH;

R_4 is C_1-C_{16} straight or branched alkyl; C_1-C_{16} alkenyl; C_1-C_{16} alkynyl; or cycloalkyl; -$(CH_2)_{1-6}$-Z_1; -$(CH_2)_{0-6}$-phenyl; and –$(CH_2)_{0-6}$-het; wherein alkyl, cycloalkyl and phenyl are unsubstituted or substituted;

Z_1 is –N(R_8)-C(O)-C_1-C_{10}alkyl; –N(R_8)-C(O)-$(CH_2)_{1-6}$-C_3-C_7cycloalkyl; –N(R_8)-C(O)-$(CH_2)_{0-6}$-phenyl; –N(R_8)-C(O)-$(CH_2)_{1-6}$-het; -C(O)-N(R_9)(R_{10}); -C(O)-O-C_1-C_{10}alkyl; -C(O)-O-$(CH_2)_{1-6}$-C_3-C_7cycloalkyl; -C(O)-O-$(CH_2)_{0-6}$-phenyl; -C(O)-O-$(CH_2)_{1-6}$-het; -O-C(O)-C_1-C_{10}alkyl; -O-C(O)-$(CH_2)_{1-6}$-C_3-C_7cycloalkyl; -O-C(O)-$(CH_2)_{0-6}$-phenyl; -O-C(O)-$(CH_2)_{1-6}$-het, wherein alkyl, cycloalkyl and phenyl are unsubstituted or substituted;

het is a 5-7 membered heterocyclic ring containing 1- 4 heteroatoms selected from N, O and S, or an 8-12 membered fused ring system including at least one 5-7 membered heterocyclic ring containing 1, 2 or 3 heteroatoms selected from N, O, and S, which heterocyclic ring or fused ring system is unsubstituted or substituted on a carbon atom by halogen, hydroxy, C_1-C_4alkyl, C_1-C_4 alkoxy, nitro, -O-C(O)-C_1-C_4alkyl or –C(O)-O-C_1-C_4-alkyl or on a nitrogen by C_1-C_4 alkyl, -O-C(O)-C_1-C_4alkyl or –C(O)-O-C_1-C_4alkyl;

R_8 is H, –CH_3, -CF_3 , -CH_2OH or -CH_2Cl;

R_9 and R_{10} are each independently H; -C_1-C_4alkyl; C_3-C_7cycloalkyl; -$(CH_2)_{1-6}$-C_3-C_7cycloalkyl; -$(CH_2)_{0-6}$-phenyl; wherein alkyl, cycloalkyl and phenyl are unsubstituted or substituted, or R_9 and R_{10} together with the nitrogen form het;

R_5 is H; C_1-C_{10}alkyl; C_3-C_7cycloalkyl; -$(CH_2)_{1-6}$-C_3-C_7cycloalkyl; -C_1-C_{10}alkyl-aryl; -$(CH_2)_{0-6}$-C_3-C_7cycloalkyl-$(CH_2)_{0-6}$-phenyl; -$(CH_2)_{0-4}$CH-$((CH_2)_{1-4}$-phenyl$)_2$; -$(CH_2)_{0-6}$-CH(phenyl)$_2$; -indanyl; -C(O)-C_1-C_{10}alkyl; -C(O)-$(CH_2)_{1-6}$-C_3-C_7cycloalkyl; -C(O)-$(CH_2)_{0-6}$-phenyl; -$(CH_2)_{0-6}$-het ; -C(O)-$(CH_2)_{1-6}$-het; or R_5 is a residue of an amino acid, wherein alkyl, cycloalkyl, phenyl and aryl are unsubstituted or substituted;

U is a as shown in structure II:



II

wherein

n = 0-5;

X is –CH or N;

Ra and Rb are independently an O, S, or N atom or C_{0-8} alkyl wherein one or more of the carbon atoms in the alkyl chain may be replaced by a heteroatom selected from O, S or N, and where the alkyl may be unsubstituted or substituted;

Rd is selected from:

(a) Re – Q – $(Rf)_p(Rg)_q$; or

(b) Ar_1–D– Ar_2 ;

p and q are independently 0 or 1;

Rc is H or Rd and Rc together form cycloalkyl or het; where if Rd and Rc form a cycloalkyl or heteroring, R_5 is attached to the formed ring at a C or N atom;

Re is C_{1-8} alkyl which may be unsubstituted or substituted;
Q is N, O, S, S(O), or $S(O)_2$;
Ar_1 and Ar_2 are substituted or unsubstituted aryl or het;
Rf and Rg are each independently H or substituted or unsubstituted C_0-C_{10}alkyl, or C_1-C_{10}alkylaryl;

D is –CO-; -C(O)-C_{1-7} alkylene or arylene; -CF_2-; -O-; -$S(O)_r$ where r is 0-2; 1,3dioaxolane; or C_{1-7} alkyl-OH; where alkyl, alkylene or arylene may be unsubstituted or substituted with one or more halogens, OH, -O-C_1-C_6alkyl, -S-C_1-C_6alkyl or -CF_3; or D is –N(Rh) wherein Rh is H; C_{1-7} alkyl (unsub or substituted); aryl; -O(C_{1-7}cycloalkyl) (unsub or substituted); C(O)-C_1-C_{10}alkyl; C(O)-C_o-C_{10}alkyl-aryl; C-O-C_1-C_{10}alkyl; C-O-C_o-C_{10}alkyl-aryl or SO_2-C_1-C_{10}-alkyl; SO_2-(C_o-C_{10}-alkylaryl);

and R_6, R_7, R'_6 and R'_7 are each independently H; -C_1-C_{10} alkyl; -OH; -O-C_1-C_{10}alkyl; -$(CH_2)_{0-6}$-C_3-C_7cycloalkyl; -O-$(CH_2)_{0-6}$-aryl; phenyl; -$(CH_2)_{1-6}$-het; -O-$(CH_2)_{1-6}$-het; -OR_{11}; -C(O)-R_{11}; –C(O)-N(R_{11})(R_{12}); -N(R_{11})(R_{12}); -S-R_{11}; -S(O)-R_{11}; -$S(O)_2$-R_{11}; -$S(O)_2$-$NR_{11}R_{12}$; -NR_{11}-$S(O)_2$- R_{12}; wherein alkyl, cycloalkyl and aryl are unsubstituted or substituted; or any R_6, R_7, R'_6 and R'_7 can be united to form a ring system;
R_{11} and R_{12} are independently H; C_1-C_{10} alkyl; -$(CH_2)_{0-6}$-C_3-C_7cycloalkyl; -$(CH_2)_{0-6}$-$(CH)_{0-1}$$(aryl)_{1-2}$; -C(O)-$C_1$-$C_{10}$alkyl; -C(O)-$(CH_2)_{1-6}$-$C_3$-$C_7$cycloalkyl; -C(O)-O-$(CH_2)_{0-6}$-aryl; -C(O)-$(CH_2)_{0-6}$-O-fluorenyl; -C(O)-NH-$(CH_2)_{0-6}$-aryl; -C(O)-$(CH_2)_{0-6}$-aryl; -C(O)-$(CH_2)_{1-6}$-het; -C(S)-$C_1$-$C_{10}$alkyl; -C(S)-$(CH_2)_{1-6}$-$C_3$-$C_7$cycloalkyl; -C(S)-O-$(CH_2)_{0-6}$-aryl; -C(S)-$(CH_2)_{0-6}$-O-fluorenyl; -C(S)-NH-$(CH_2)_{0-6}$-aryl; -C(S)-$(CH_2)_{0-6}$-aryl; -C(S)-$(CH_2)_{1-6}$-het, wherein alkyl, cycloalkyl and aryl are unsubstituted or substituted; or R_{11} and R_{12} are a substituent that facilitates transport of the molecule across a cell membrane; or R_{11} and R_{12} together with the nitrogen are het; aryl of R_{11} and R_{12} can be phenyl, naphthyl, or indanyl which is unsubstituted or substituted;
alkyl of R_{11} and R_{12} may be unsubstituted or substituted by one or more substituents selected from a C_1-C_{10} alkene, halogen, OH, -O-C_1-C_6alkyl, -S-C_1-C_6alkyl and –CF_3;

cycloalkyl of R_{11} and R_{12} may be unsubstituted or substituted by one or more selected from a C_1-C_{10} alkene, one or more halogens, C_1-C_6alkyl, halogen, OH, -O-C_1-C_6alkyl, -S-C_1-C_6alkyl or $-CF_3$; and

phenyl or aryl of R_{11} and R_{12} may be unsubstituted or substituted by one or more substituents selected from halogen, hydroxy, C_1-C_4 alkyl, C_1-C_4 alkoxy, nitro, -CN, -O-C(O)-C_1-C_4alkyl and $-C(O)$-O-C_1-C_4-aryl;

or pharmaceutically acceptable salts thereof.

3. A compound according to Claim 1 wherein

R_1 and R_2 are independently H or substituted or unsubstituted C_1-C_4alkyl;

R_4 is C_1-C_{16} straight or branched alkyl, or C_3-C_{10}cycloalkyl, wherein the alkyl or cycloalkyl may be unsubstituted or substituted;

R_5 is H; C_1-C_{10}alkyl; C_1-C_{10}alkyl-aryl; -C(O)-$(CH_2)_{0-6}$-Phenyl; -$(CH_2)_{0-6}$-C(O)- Phenyl; aryl; indanyl; naphthyl or R_5 is a residue of an amino acid, wherein the alkyl or aryl substituents are unsubstituted or substituted;

U is as shown in structure II:



II

wherein

n = 0-5;

X is –CH or N;

Ra and Rb are independently an O, S, or N atom or C_{0-8} alkyl wherein one or more of the carbon atoms in the alkyl chain may be replaced by a heteroatom selected from O, S or N, and where the alkyl may be unsubstituted or substituted;

Rd is selected from

(a) --Re – Q – $(Rf)_p(Rg)_q$; or

(c) Ar_1–D– Ar_2;

Rc is H or Rc and Rd together form cycloalkyl or het; where if Rd and Rc form a cycloalkyl or heteroring, R_5 is attached to the formed ring at a C or N atom;
p and q are independently 0 or 1;
Re is C_{1-8} alkyl, or methylidene which may be unsubstituted or substituted;
Q is N, O, S, S(O), or $S(O)_2$;
Ar_1 and Ar_2 are substituted or unsubstituted aryl or het;
Rf and Rg are each independently H or substituted or unsubstituted C_0-C_{10}alkyl; C_1-C_{10}alkylaryl; aryl-C_1-C_{10}alkyl; het-C_1-C_{10}alkyl -C(O)-C_1-C_4-alkyl-phenyl; -C(O)-C_1-C_4-alkyl; -SO_2-C_1-C_2alkyl; -SO_2-C_1-C_2alkylphenyl; -O-C_1-C_4-alky;

D is –C(O)-; C_{1-7} alkylene or arylene; –O-, or -$S(O)_r$ where r is 0-2; where alkyl, alkylene or arylene which may be unsubstituted or substituted with one or more halogens; -OH; -O-C_1-C_6alkyl; -S-C_1-C_6alkyl or -CF_3; or D is NRh wherein Rh is H; C_{1-7} alkyl (unsubtituted or substituted); aryl; -OC_{1-7} cycloalkyl (unsubstituted or substituted); -CO-C_{0-10} alkyl or aryl or SO_2-C_{0-10} -alkyl or aryl; and R_6, R_7, R'_6 and R'_7 are each independently H, -C_1-C_{10} alkyl, or –OH, alkoxy, or aryloxy;
or pharmaceutically acceptable salts thereof.

4. A compound according to Claim 1 wherein
U is a bicyclic saturated or unsaturated ring system, consisting of all carbon skeleton or with one or more heteroatoms such as O, N, S but preferably as shown in structure III:



III

wherein

wherein any of the ring carbon atoms can be unsubstituted or substituted with any of the substituted defined above for R_6, R_7, $R_{6'}$ and R_7';
X is CH or N;
V is O, F_2, Cl_2, Br_2, I_2, S, YH, H_2, NH, or C_1-C_4 alkyl;
W is -CH, or -N;
n is 0-3; and
m is 0-3.

5. A compound according to Claim 1 wherein the ring carbon atoms on U are substituted with subsituents independently selected from halo, H, OH, lower alkyl or lower alkoxy, wherein alkyl or alkoxy are unsubstituted or substituted by halogen, OH, lower alkyl or lower alkoxy.

6. A compound according to Claim 1 wherein
R_1 and R_3 are preferably methyl or ethyl;
R_2 is especially H methyl, ethyl, chloromethyl, dichloromethyl or trifluoromethyl;
R_4 is -C_1-C_4alkyl; -C_3-C_7 cycloalky; –$(CH_2)_{1\text{-}6}$cycloalkyl; or –$(CH_2)_{0\text{-}6}$aryl;
R_5 is -C_1-C_4alkyl-phenyl; -C(O)-C_1-C_4-alkyl-phenyl; -C_1-C_4-C(O)-alkyl-pheny or aryl,R_5 is particularly phenylmethyl, phenylethyl and phenylpropyl; indanyl, naphthyl; -C(O)–CH_2-phenyl or –CH_2-C(O)–phenyl;
R_6 and R_7 are H or methyl;
U has the structure of formula III:



III

wherein

wherein any of the ring carbon atoms can be unsubstituted or substituted with any of the substituted defined above for R_6, R_7, $R_{6'}$ and R_7';
X is N;
V is O or H_2;
W is -N;
n is 1; and
m is 1 or 2.

7. A compound according to Claim 1 wherein
R_1 and R_3 are preferably methyl or ethyl;
R_2 is H;
R_4 is C_1-C_4alkyl; C_3-C_7 cycloalkyl; C_1-C_7 cycloalkyl-C_1-C_7alkyl; phenyl-C_1-C_7alkyl or aryl. R_4 is particularly methyl, ethyl, butyl, isopropyl, t-butyl, or cyclohexyl; -CH_2-cyclopentyl, -CH_2-cyclohexyl; -CH_2-cyclopropyl; phenyl or –CH_2-phenyl;
R_5 is -C_1-C_4-alkyl-phenyl; -C(O) -C_1-C_4-alkyl-phenyl; -C_1-C_4 -C(O) -alkyl-pheny or aryl. R_5 is particularly phenylethyl; indanyl, naphthyl; -C(O) –CH_2-phenyl; –CH_2 -C(O) –phenyl; or (CF_3O)phenylethyl;
R_6, R'_6, R_7 and R'_7 are H;
U has the structure of formula III wherein
wherein any of the ring carbon atoms can be unsubstituted or substituted with any of the substituted defined above for R_6, R_7, $R_{6'}$ and R_7';
X is N;
V is O or H_2;
W is -N;
n is 1; and
m is 1 or 2.

8. A compound according to Claim 1 wherein
R_1 and R_3 are preferably methyl or ethyl;
R_2 is especially H, methyl, ethyl, chloromethyl, dichloromethyl or trifluoromethyl;

R_4 is C_1-C_4alkyl or C_3-C_7 cycloalkyl particularly isopropyl, t-butyl, cyclopentyl, or cyclohexyl;
R_5 is H;
U has the structure of formula II wherein
X is N;
R_6, R'_6, R_7, and R'_7 are H;
n is O;
Rc is H;
Ar_1 and Ar_2 are substituted or unsubstituted phenyl or het particularly tetrazolyl, 1, 2,3-triazole, pyrazole, oxazole, pyrrolyl, triazine, pyrimidine, imidazol, oxadiazol; and and D is C_1 alkyl which may optionally be substituted with halo, especially F.

9. A compound according to Claim 1 wherein
R_1 and R_3 are preferably methyl or ethyl;
R_2 is especially H, methyl, ethyl, chloromethyl, dichloromethyl or trifluoromethyl;
R_4 is C_1-C_4alkyl; C_3-C_7 cycloalkyl; C_1-C_7 cycloalkyl-C_1-C_7alkyl; phenyl-C_1-C_7alkyl or aryl;
R_5 is H;
U has the structure of formula II wherein
X is N;
R_6, R'_6, R_7, and R'_7 are H; or R_6 is -C(O)-C_1-C_4-alkyl-phenyl and R'_6, R_7, and R'_7 are H;
n is O;
Rc is H;
Ar_1 and Ar_2 are substituted or unsubstituted phenyl or het, particularly triazine, pyrimidine, pyridine, oxazole, 2,4-difluorophenyl, Cl-phenyl or fluorophenyl; and D is N(Rh), where Rh is H, Me, -CHO, -SO_2, -C(O), -CHOH, CF_3 or –SO_2CH_3.

10. A compound according to Claim 1 wherein
R_1 and R_3 are preferably methyl or ethyl;
R_2 is especially H, methyl, ethyl, chloromethyl, dichloromethyl or trifluoromethyl;

R_4 is C_1-C_4alkyl; C_3-C_7 cycloalkyl; C_1-C_7 cycloalkyl- C_1-C_7alkyl; phenyl-C_1-C_7alkyl or aryl. R_4 is particularly methyl, ethyl, butyl, isopropyl, t-butyl, or cyclohexyl; -CH_2-cyclopentyl, -CH_2-cyclohexyl; -CH_2-cyclopropyl; phenyl or –CH_2-phenyl;
R_5 is H;
U has the structure of formula II wherein
X is N;
R_6, R'_6, R_7, and R'_7 are H;
n is O;
Rc is H;
Ar_1 and Ar_2 are substituted or unsubstituted phenyl or het particularly pyrimidine, pyridine, oxazole, 2-methyloxazole;
and D is –O-.

11. A compound according to Claim 1 wherein
R_1 and R_3 are preferably methyl or ethyl;
R_2 is especially H, methyl, ethyl, chloromethyl, dichloromethyl or trifluoromethyl;
R_4 is C_1-C_4alkyl or C_3-C_7 cycloalkyl particularly isopropyl, t-butyl, cyclopentyl, or cyclohexyl;
R_5 is H;
U has the structure of formula II wherein
X is N;
R_6, R'_6, R_7, and R'_7 are H;
n is O;
Rc is H;
Ar_1 and Ar_2 are substituted or unsubstituted phenyl or het;
and D is S, S(O), or $S(O)_2$.

12. A compound according to Claim 1 wherein
R_1 and R_3 are preferably methyl or ethyl;
R_2 is especially H, methyl, ethyl, chloromethyl, dichloromethyl or trifluoromethyl;

R_4 is C_1-C_4alkyl or C_3-C_7 cycloalkyl particularly isopropyl, t-butyl, cyclopentyl, or cyclohexyl;
R_5 is H;
U has the structure of formula II wherein
X is N;
R_6, R'_6, R_7, and R'_7 are H;
n is O;
Rc is H;
Ar_1 and Ar_2 are substituted or unsubstituted phenyl or het, particularly oxazole, thaizole and ozadiazole;
and D is C(O), or 1,3-dioxolane.

13. A compound according to Claim 1 wherein
R_1 and R_3 are preferably methyl or ethyl;
R_2 is especially H, methyl, ethyl, chloromethyl, dichloromethyl or trifluoromethyl;
R_4 is C_1-C_4alkyl or C_3-C_7 cycloalkyl particularly isopropyl, t-butyl, cyclopentyl, or cyclohexyl;
R_5 is H or phenyl C_1-C_{10} alkyl such as phenylethyl;
U has the structure of formula II wherein
X is N;
R_6, R'_6, R_7, and R'_7 are H;
n is O;
Rc and Rd are het, particularly pyrrolidine; pyrrolidin-2-one; or pyrrolidin-3-one.

14. A compound according to Claim 1 wherein
R_1 and R_3 are preferably methyl or ethyl;
R_2 is especially H, methyl, ethyl, chloromethyl, dichloromethyl or trifluoromethyl;
R_4 is C_1-C_4alkyl or C_3-C_7 cycloalkyl particularly isopropyl, t-butyl, cyclopentyl, or cyclohexyl;
R_5 is H, indanyl or phenyl;
U has the structure of formula II wherein

X is N;
Q is O;
R_6, R'_6, R_7, and R'_7 are H;
n is O;
Re is C_1 alkyl; and
p and q are 0.

15. A compound according to Claim 1 wherein
R_1 and R_3 are preferably methyl or ethyl;
R_2 is especially H, methyl, ethyl, chloromethyl, dichloromethyl or trifluoromethyl;
R_4 is C_1-C_4alkyl or C_3-C_7 cycloalkyl particularly isopropyl, t-butyl, cyclopentyl, or cyclohexyl;
R_5 is H, indanyl or phenyl;
U has the structure of formula II wherein
X is N;
Q is N;
R_6, R'_6, R_7, and R'_7 are H;
n is O;
Re is C_1 alkyl; and
R_9 is H, C_1-C_8 alkyl, methyl, ethyl, hexyl, heptyl, octyl, or CH_2CF_3, or aryl-C_1-C_4 alkyl particularly phenylethyl, furanylethyl; C_3-C_7 cycloalkyl particularly cyclohexyl; ethylphenyl; -C(O) -C_1-C_4-alkyl-phenyl; -C(O) -C_1-C_4-alkyl; -C_1-C_4-alkyl-aryl particularly –CH_2-phenyl; –CH_2-thiophene, –CH_2-furan, –CH_2-pyrrolidinyl, –CH_2-imidazole, –CH_2-triazole, –CH_2-imidazole;
and R_f is C_1-C_2 alkyl; C_1-C_2 alkylphenyl; -SO_2-C_1-C_2alkyl; -SO_2-C_1-C_2alkylphenyl; -O-C_1-C_4-alkyl particularly O-ethyl; phenyl-phenyl, 1,2,3,4tetrahydronapthalene and indanyl.

16. A compound according to Claim 1 wherein
R_1 and R_3 are preferably methyl or ethyl;
R_2 is especially H, methyl, ethyl, chloromethyl, dichloromethyl or trifluoromethyl;

R_4 is C_1-C_4alkyl or C_3-C_7 cycloalkyl particularly isopropyl, t-butyl, cyclopentyl, or cyclohexyl;
R_5 is H, indanyl or phenyl;
U has the structure of formula II wherein
X is N;
Q is N;
R_6, R'_6, R_7, and R'_7 are H;
n is O;
Re is C_1 alkyl; and
R_g and R_f form a ring selected from het or aryl particularly 2,3,4,5-tetrahydrobenzo[c]azepine; 1,2,3,4 tetrahydroquinoline; indanyl which may be substituted with C_1-C_4alkylphenyl

17. A compound according to Claim 1 wherein
R_1 and R_3 are preferably methyl or ethyl;
R_2 is especially H, methyl, ethyl, chloromethyl, dichloromethyl or trifluoromethyl;
R_4 is C_1-C_4alkyl or C_3-C_7 cycloalkyl particularly isopropyl, t-butyl, cyclopentyl, or cyclohexyl;
R_5 is phenyl;
U has the structure of formula II wherein
X is N;
Q is O, S, S(O) or $S(O)_2$;
R_6, R'_6, R_7, and R'_7 are H;
n is O;
Re is C_1 alkyl;
q is 0;
Rc is H;
and R_f is C_2 alkyl.

18. A compound according to Claim 1 wherein R_3 and R_4 have the stereochemistry indicated in formula IV, with the definitions of the variable substituents and

preferences described herein above also applying to compounds having the stereochemistry indicated in formula IV.



IV

19. A compound according to Claim 18 wherein compound with the stereochemistry of formula (IV) wherein

R_1 and R_3 are preferably methyl or ethyl;

R_2 is H, methyl, ethyl, or substituted methyl especially chloromethyl, dichloromethyl and trifluoromethyl; preferably R_2 is H or unsubstituted methyl;

R_4 is C_1-C_4alkyl or C_3-C_7 cycloalkyl particularly isopropyl, t-butyl, cyclopentyl, or cyclohexyl;

R_5 is -C_1-C_4-alkyl-phenyl, particularly phenylmethyl, phenylethyl and phenylpropyl, indanyl, naphthyl; and

R_6 and R_7 are H or methyl.

20. A compound according to Claim 1 wherein the stereochemistry for U is as shown in Figure V



V

21. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of formula I according to claim 1.

22. A method of treating a proliferative disease which comprises administering a therapeutically effective amount of a compound of formula I according to claim 1 to a mammal in need of such treatment.

23. A method of claim 22 wherein the mammal is a human.

24. A compound selected from:

N-[1-Cyclohexyl-2-oxo-2-(6-phenethyl-octahydro-pyrrolo[2,3-*c*]pyridin-1-yl)-ethyl]-2-methylamino-acetamide;

2-Methylamino-*N*-[2-methyl-1-(7-oxo-6-phenethyl-octahydro-pyrrolo[2,3-*c*]pyridine-1-carbonyl)-propyl]-propionamide;

2-Methylamino-*N*-[2-methyl-1-(7-oxo-6-phenethyl-octahydro-pyrrolo[2,3-*c*]pyridine-1-carbonyl)-propyl]-propionamide;

2-Methylamino-*N*-[2-methyl-1-(8-oxo-7-phenethyl-octahydro-pyrrolo[2,3-*c*]azepine-1-carbonyl)-propyl]-propionamide;

2-Methylamino-*N*-[2-methyl-1-(7-oxo-6-phenethyl-octahydro-pyrrolo[2,3-*c*]pyridine-1-carbonyl)-propyl]-butyramide;

2-Methylamino-*N*-[2-methyl-1-(7-oxo-6-phenethyl-octahydro-pyrrolo[2,3-*c*]pyridine-1-carbonyl)-propyl]-butyramide;

2-Methylamino-*N*-[2-methyl-1-(8-oxo-7-phenethyl-octahydro-pyrrolo[2,3-*c*]azepine-1-carbonyl)-propyl]-butyramide;

N-[1-Cyclohexyl-2-oxo-2-(7-oxo-6-phenethyl-octahydro-pyrrolo[2,3-*c*]pyridin-1-yl)-ethyl]-2-methylamino-propionamide;

2-Methylamino-*N*-{2-methyl-1-[5-(3-methyl-hexa-3,5-dienyl)-6-oxo-hexahydro-pyrrolo[3,4-*b*]pyrrole-1-carbonyl]-propyl}-propionamide;

2-Methylamino-*N*-[2-methyl-1-(3-methyl-7-oxo-6-phenethyl-octahydro-pyrrolo[2,3-*c*]pyridine-1-carbonyl)-propyl]-propionamide;

2-Methylamino-*N*-[2-methyl-1-(3-methyl-7-oxo-6-phenethyl-octahydro-pyrrolo[2,3-*c*]pyridine-1-carbonyl)-propyl]-propionamide;

N-[1-(4-Benzyloxy-7-oxo-6-phenethyl-octahydro-pyrrolo[2,3-*c*]pyridine-1-carbonyl)-2-methyl-propyl]-2-methylamino-propionamide;

N-[1-Cyclohexyl-2-oxo-2-(8-oxo-7-phenethyl-octahydro-pyrrolo[2,3-*c*]azepin-1-yl)-ethyl]-2-methylamino-butyramide;

N-[1-Cyclohexyl-2-oxo-2-(8-oxo-7-phenethyl-octahydro-pyrrolo[2,3-*c*]azepin-1-yl)-ethyl]-2-methylamino-butyramide;

N-[1-Cyclohexyl-2-oxo-2-(7-phenethyl-octahydro-pyrrolo[2,3-*c*]azepin-1-yl)-ethyl]-2-methylamino-propionamide;

2-Methylamino-*N*-[2-methyl-1-(8-oxo-7-phenethyl-octahydro-pyrrolo[2,3-*c*]azepine-1-carbonyl)-propyl]-butyramide;

(S)-N-{(S)-2-[(R)-2-(3-Benzyl-phenyl)-pyrrolidin-1-yl]-1-cyclohexyl-2-oxo-ethyl}-2-methylamino-propionamide;

(S)-N-{(S)-2-[(S)-2-(3-Benzyl-pheny l)-pyrrolidin-1-yl]-1-cyclohexyl-2- oxo-ethyl}-2-methylamino-propionamide;

(S)-2-Methylamino-N-((S)-2-methyl-1 -{(S)-2-[3-(methyl-phenyl-amino)-phenyl]-pyrrolidine-1-carbonyl}-propy l)-propionamide;

(S)-N-((S)-1-Cyclohexyl-2-{(S)-2-[3 -(methyl-phenyl-amino)-phenyl]-pyrrolidin-1-yl}-2-oxo-ethyl)-2-methylamino-propionamide;

(S)-N-((S)-1-Cyclohexyl-2-{(R)-2-[3 -(methyl-phenyl-amino)-phenyl]-pyrrolidin-1-yl}-2-oxo-ethyl)-2-methylamino-propionamide;

(S)-N-{(S)-1-Cyclohexyl-2-oxo-2-[(R)-2-(3-phenoxy-phenyl)-pyrrolidin-1 -yl]-ethyl}-2-methylamino-propionamide;

(S)-N-{(S)-1-Cyclohexyl-2-oxo-2-[(S)-2-(3-phenoxy-phenyl)-pyrrolidin-1 -yl]-ethyl}-2-methylamino-propionamide;

(S)-N-{(S)-1-Cyclohexyl-2-oxo-2-[(R)-2-(3-phenylsulfanyl-phenyl)-pyrrolidin-1-yl]-ethyl}-2-methylamino-propionamide;

(S)-N-{(S)-1-Cyclohexyl-2-oxo-2-[(S)-2-(3-phenylsulfanyl-phenyl)-pyrrolidin-1-yl]-ethyl}-2-methylamino-propionamide;

(S)-N-{(S)-2-[(R)-2-(3-Benzenesulfonyl-phenyl)-pyrrolidin-1-yl]-1-cyclohexyl-2-oxo-ethyl}-2-methylamino-propionamide;

(S)-N-{(S)-2-[(S)-2-(2-Benzyl-2H-tetrazol-5-yl)-pyrrolidin-1-yl]-1-cyclohexyl-2-oxo-ethyl}-2-methylamino-propionamide;

(S)-N-{(S)-2-[(S)-2-(2-Benzyl-2H-tetrazol-5-yl)-pyrrolidin-1-yl]-1-cyclohexyl-2-oxo-ethyl}-2-methylamino-butyramide;

(S)-N-{(S)-2-[(S)-2-(1-Benzyl-1H-te trazol-5-yl)-pyrrolidin-1-yl]-1-cyclohexyl-2-oxo-ethyl}-2-methylamino- propionamide;

(S)-N-{(S)-2-[(S)-2-(1-Benzyl-1H-te trazol-5-yl)-pyrrolidin-1-yl]-1-cyclohexyl-2-oxo-ethyl}-2-methylamino-butyramide;

(S)-N-{(S)-2-[2-(Benzyloxyimino- hyl)-pyrrolidin-1-yl]-1-cyclohexyl- 2-oxo-ethyl}-2-methylamino-propionamide;

(S)-2-Methylamino-N-{(S)-2-methyl-1 -[2-((S)-phenylmethanesulfonylamino -methyl)-pyrrolidine-1-carbonyl]-pr opyl}-propionamide;

(S)-2-Methylamino-N-{(S)-2-methyl-1 -[2-((S)-phenylmethanesulfonylamino -methyl)-pyrrolidine-1-carbonyl]-pr opyl}-butyramide;

N-(1-Cyclohexyl-2-{(S)-2-[(ethyl-indan-2-yl-amino)-methyl]-pyrrolidin- 1-yl}-2-oxo-ethyl)-2-((S)-methylamino)-propionamide;

(S)-N-[(S)-1-Cyclohexyl-2-(2-{[(S)- indan-2-yl-(2,2,2-trifluoro-ethyl)- amino]-methyl}-pyrrolidin-1-yl)-2-oxo-ethyl]-2-methylamino-propionamide;

(S)-N-((S)-1-Cyclohexyl-2-{2-[((S)- cyclohexyl-phenethyl-amino)-methyl] -pyrrolidin-1-yl}-2-oxo-ethyl)-2-methylamino-propionamide;

(S)-N-((S)-2-{2-[((S)-tert-Butyl-phenethyl-amino)-methyl]-pyrrolidin-1 -yl}-1-cyclohexyl-2-oxo-ethyl)-2-methylamino-propionamide;

(S)-N-((S)-1-Cyclohexyl-2-{2-[((S)- furan-2-ylmethyl-phenethyl-amino)-methyl]-pyrrolidin-1-yl}-2-oxo-ethyl)-2-methylamino-propionamide;

(S)-N-[(S)-1-Cyclohexyl-2-oxo-2-(2- {[(S)-phenethyl-(4-phenyl-butyl)-amino]-methyl}-pyrrolidin-1-yl)-ethyl]-2-methylamino-propionamide;

(S)-N-[(S)-1-Cyclohexyl-2-(2-{[(S)- methyl-(4-phenyl-butyl)-amino]-methyl}-pyrrolidin-1-yl)-2-oxo-ethyl]-2 -methylamino-propionamide;

N-[(S)-1-(S)-Cyclohexyl-2-oxo-2-((R)-6-phenethyl-octahydro-pyrrolo[2,3 -c]pyridin-1-yl)-ethyl]-acetamide;

(S)-N-[(S)-1-(S)-Cyclohexyl-2-oxo-2 -((R)-6-phenethyl-octahydro-pyrrolo [2,3-c]pyridin-1-yl)-ethyl]-2-methylamino-butyramide;

(S)-2-Methylamino-N-[(S)-2-methyl-1 -((R)-6-phenethyl-octahydro-pyrrolo [2,3-c]pyridine-1-carbonyl)-propyl] -propionamide;

(S)-N-[(S)-2,2-Dimethyl-1-((R)-6-phenethyl-octahydro-pyrrolo[2,3-c]pyridine-1-carbonyl)-propyl]-2-methylamino-propionamide;

(S)-2-Methylamino-N-[(S)-2-methyl-1 -((R)-6-phenethyl-octahydro-pyrrolo [2,3-c]pyridine-1-carbonyl)-propyl] -butyramide;

(S)-N-[(S)-2,2-Dimethyl-1-((3aR,7aS)-6-phenethyl-octahydro-pyrrolo[2,3 -c]pyridine-1-carbonyl)-propyl]-2-methylamino-propionamide;

(S)-N-((S)-1-Cyclohexyl-2-oxo-2-{(3 aR,7aS)-6-[2-(2-trifluoromethoxy-phenyl)-ethyl]-octahydro-pyrrolo[2,3- c]pyridin-1-yl}-ethyl)-2-methylamino-propionamide;

(S)-N-((S)-1-Cyclohexyl-2-oxo-2-{(3 aR,7aS)-6-[2-(3-trifluoromethoxy-phenyl)-ethyl]-octahydro-pyrrolo[2,3- c]pyridin-1-yl}-ethyl)-2-methylamino-propionamide;

(S)-N-[(S)-1-Cyclohexyl-2-oxo-2-((3 aR,6aR)-5-phenethyl-hexahydro-pyrrolo[3,4-b]pyrrol-1-yl)-ethyl]-2-methylamino-butyramide;

(S)-N-[(S)-1-Cyclohexyl-2-oxo-2-((3 aS,6aS)-5-phenethyl-hexahydro-pyrrolo[3,4-b]pyrrol-1-yl)-ethyl]-2-methylamino-butyramide;

(S)-N-[(S)-1-Cyclohexyl-2-oxo-2-((3 aS,6aS)-5-phenethyl-hexahydro-pyrrolo[3,4-b]pyrrol-1-yl)-ethyl]-2-methylamino-propionamide;

(S)-N-[(S)-1-Cyclohexyl-2-oxo-2-((3 aS,6aS)-6-oxo-5-phenethyl-hexahydro - pyrrolo[3,4-b]pyrrol-1-yl)-ethyl]- 2-methylamino-butyramide;

(S)-N-[(R)-1-Cyclohexyl-2-oxo-2-((3 aS,6aS)-6-oxo-5-phenethyl-hexahydro - pyrrolo[3,4-b]pyrrol-1-yl)-ethyl]- 2-methylamino-butyramide;

(S)-N-[(S)-1-Cyclohexyl-2-oxo-2-((3 aS,6aS)-6-oxo-5-phenethyl-hexahydro - pyrrolo[3,4-b]pyrrol-1-yl)-ethyl]- 2-methylamino-propionamide;

(S)-N-[(R)-1-Cyclohexyl-2-oxo-2-((3 aS,6aS)-6-oxo-5-phenethyl-hexahydro - pyrrolo[3,4-b]pyrrol-1-yl)-ethyl]- 2-methylamino-propionamide;

(S)-N-[(S)-1-(R)-Cyclohexyl-2-oxo-2 -((S)-7-phenethyl-octahydro-pyrrolo [2,3-c]azepin-1-yl)-ethyl]-2-methylamino-propionamide;

(S)-N-[(S)-1-(S)-Cyclohexyl-2-oxo-2 -((R)-8-oxo-7-phenethyl-octahydro-pyrrolo[2,3-c]azepin-1-yl)-ethyl]-2- methylamino-butyramide; and pharmaceutically acceptable salts thereof.

25. A compound selected from

N-[1-cyclohexyl-2-oxo-2-(6-phenethyl-octahydro-pyrrolo[2,3-c]pyridin-1-yl)-ethyl]-2-methylamino-propionamide;

N-{1-cyclohexyl-2-oxo-2-(2-(3-phenoxy-phenyl) pyrrolidin-1-yl]-ethyl}-2-methylamino-propionamide;

N-[1-cyclohexyl-2-oxo-2-(7-phenethyl-octahydro-pyrrolo[2,3-c]azepin-1-yl)-ethyl]-2-methylaminopropionamide;
(S)-N-((S)-1-Cyclohexyl-2-{(2S,3R)-2-[(ethyl-phenethyl-amino)-methyl]-3-methyl-pyrrolidin-1-yl}-2-oxo-ethyl)-2-methylamino-propionamide;

N-{2-[2-(2-benzyl-2H-tetrazol-5-yl)-pyrrolidin-1-yl]-cyclohexyl-2-oxo-ethyl}-2-methylamino-butyramide;

N-{2-[2-Benxyloxyimino-methyl)-pyrrolidin-1-yl}-1-cyclohexyl-2-oxo-ethyl-2-methylamino-propionamide; and pharmaceutically acceptable salts thereof.

26. A compound selected from
(S)-N-{(S)-1-Cyclohexyl-2-oxo-2-[(S)-2-(3-phenoxy-phenyl)-pyrrolidin-1-yl]-ethyl}-2-methylamino-propionamide;

(S)-N-{(S)-1-Cyclohexyl-2-oxo-2-[(S)-2-(3-phenylsulfanyl-phenyl)-pyrrolidin-1-yl]-ethyl}-2-methylamino-propionamide;

(S)-N-{(S)-2-[(S)-2-(2-Benzyl-2H-tetrazol-5-yl)-pyrrolidin-1-yl]-1-cyclohexyl-2-oxo-ethyl}-2-methylamino-propionamide;

(S)-N-{(S)-2-[(S)-2-(2-Benzyl-2H-tetrazol-5-yl)-pyrrolidin-1-yl]-1-cyclohexyl-2-oxo-ethyl}-2-methylamino-butyramide;

(S)-N-{(S)-2-[(S)-2-(1-Benzyl-1H-tetrazol-5-yl)-pyrrolidin-1-yl]-1-cyclohexyl-2-oxo-ethyl}-2-methylamino-propionamide;

(S)-N-{(S)-2-[(S)-2-(1-Benzyl-1H-tetrazol-5-yl)-pyrrolidin-1-yl]-1-cyclohexyl-2-oxo-ethyl}-2-methylamino-butyramide; and pharmaceutically accpetable salts thereof